STOCK TITAN
  1. Home
  2. Sec-filings
  3. PRME
  4. [Form 4] Prime Medicine, Inc. Insider Trading Activity

Prime Medicine (PRME) awards director David Schenkein 75,000 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Prime Medicine director David P. Schenkein received a grant of stock options for 75,000 shares of common stock. The options have an exercise price of $3.06 per share and expire on June 5, 2036. Following this grant, he holds options on 75,000 shares.

The options will vest in full on the earlier of June 5, 2027 or the date of Prime Medicine’s next annual meeting of stockholders, provided he remains in continuous service with the company through that vesting date. This is a compensation-related, non‑market transaction.

Positive

  • None.

Negative

  • None.
Insider Schenkein David P
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 75,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 75,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 75,000 options Stock Option (right to buy) granted to director
Exercise price $3.06 per share Conversion or exercise price of granted options
Expiration date June 5, 2036 Option expiration for the 75,000-share grant
Total options after grant 75,000 options Total derivative holdings following this transaction
Vesting date outer limit June 5, 2027 Latest date when options vest in full, subject to service
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 3.0600"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in full financial
"The shares subject to this option shall vest in full upon the earlier"
annual meeting of stockholders financial
"or (ii) the date of the next annual meeting of stockholders"
continuous service financial
"subject to the Reporting Person's continuous service to the Issuer"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Schenkein David P
(Last)(First)(Middle)
C/O PRIME MEDICINE, INC.
60 FIRST STREET
(Street)
CAMBRIDGE MASSACHUSETTS 02141
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Prime Medicine, Inc. [ PRME ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$3.0606/05/2026A75,000 (1)06/05/2036Common Stock75,000$075,000D
Explanation of Responses:
1. The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Remarks:
/s/ Ryan Brown, attorney-in-fact06/08/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Prime Medicine (PRME) report in this Form 4 filing?

Prime Medicine reported a compensation-related stock option grant to director David P. Schenkein. He received options on 75,000 shares of common stock, with specific vesting terms, an exercise price, and an expiration date disclosed in the filing.

How many stock options did David P. Schenkein receive from Prime Medicine (PRME)?

David P. Schenkein received stock options for 75,000 shares of Prime Medicine common stock. These options represent the entire derivative position reported in this filing and are shown as his total options following the transaction.

What are the vesting terms of the Prime Medicine (PRME) stock options granted?

The options vest in full on the earlier of June 5, 2027 or the date of Prime Medicine’s next annual meeting of stockholders. Vesting is conditioned on David P. Schenkein’s continuous service to the company through the applicable vesting date.

What is the exercise price and expiration date of the Prime Medicine (PRME) options?

The granted stock options carry an exercise price of $3.06 per share and expire on June 5, 2036. These terms define the cost to purchase shares and the final date by which the options must be exercised.

Is the Prime Medicine (PRME) Form 4 transaction an open-market trade?

No. The Form 4 describes a grant or award of stock options as compensation, not an open-market purchase or sale. It is recorded with transaction code “A,” indicating a grant, award, or other acquisition from the issuer.